FULC

Company Overview — What Does Fulcrum Therapeutics, Inc. Do?

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has research and discovery collaboration agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and has a strategic collaboration and license agreement with MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts. Fulcrum Therapeutics, Inc. (FULC) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Bryan E. Stuart and employs approximately 100 people. With a market capitalization of $498M, FULC is one of the notable companies in the Healthcare sector.

Fulcrum Therapeutics, Inc. (FULC) Stock Rating — Reduce (April 2026)

As of April 2026, Fulcrum Therapeutics, Inc. receives a Reduce rating with a composite score of 37.9/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.FULC ranks #3,092 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Fulcrum Therapeutics, Inc. ranks #450 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

FULC Stock Price and 52-Week Range

Fulcrum Therapeutics, Inc. (FULC) currently trades at $7.55. The stock lost $0.36 (4.6%) in the most recent trading session. The 52-week high for FULC is $15.74, which means the stock is currently trading -52.0% from its annual peak. The 52-week low is $2.31, putting the stock 226.1% above its annual trough. Recent trading volume was 1.1M shares, reflecting moderate market activity.

Is FULC Overvalued or Undervalued? — Valuation Analysis

Fulcrum Therapeutics, Inc. (FULC) carries a value factor score of 33/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 2.63x, versus the sector average of 2.75x.

At current multiples, Fulcrum Therapeutics, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Fulcrum Therapeutics, Inc. Profitability — ROE, Margins, and Quality Score

Fulcrum Therapeutics, Inc. (FULC) earns a quality factor score of 26/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -38.4%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -35.5% versus the sector average of -33.1%.

Revenue growth is running at -100.0% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

FULC Debt, Balance Sheet, and Financial Health

Fulcrum Therapeutics, Inc. has a debt-to-equity ratio of 0.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. Total debt on the balance sheet is $0. Cash and equivalents stand at $47M.

FULC has a beta of 1.16, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for Fulcrum Therapeutics, Inc. is 26/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Fulcrum Therapeutics, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Fulcrum Therapeutics, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.31. Net income for the quarter was $-76M. Operating income came in at $-87M.

In Q3 2025, Fulcrum Therapeutics, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.31. Net income for the quarter was $-20M. Operating income came in at $-22M.

In Q2 2025, Fulcrum Therapeutics, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.28. Net income for the quarter was $-17M. Operating income came in at $-20M.

In Q1 2025, Fulcrum Therapeutics, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.28. Net income for the quarter was $-18M. Operating income came in at $-20M.

Over the past 8 quarters, Fulcrum Therapeutics, Inc. has experienced revenue contraction from $0 to $0. Investors analyzing FULC stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

FULC Dividend Yield and Income Analysis

Fulcrum Therapeutics, Inc. (FULC) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

FULC Momentum and Technical Analysis Profile

Fulcrum Therapeutics, Inc. (FULC) has a momentum factor score of 53/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 40/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 54/100 reflects moderate short selling activity.

FULC vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Fulcrum Therapeutics, Inc. (FULC) ranks #450 out of 838 stocks based on the Blank Capital composite score. This places FULC in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing FULC against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full FULC vs S&P 500 (SPY) comparison to assess how Fulcrum Therapeutics, Inc. stacks up against the broader market across all factor dimensions.

FULC Next Earnings Date

No upcoming earnings date has been announced for Fulcrum Therapeutics, Inc. (FULC) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy FULC? — Investment Thesis Summary

The quantitative profile for Fulcrum Therapeutics, Inc. suggests caution. The quality score of 26/100 flags below-average profitability. The value score of 33/100 indicates premium valuation. High volatility (stability score 26/100) increases portfolio risk.

In summary, Fulcrum Therapeutics, Inc. (FULC) earns a Reduce rating with a composite score of 37.9/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on FULC stock.

Related Resources for FULC Investors

Explore more research and tools: FULC vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare FULC head-to-head with peers: FULC vs AZN, FULC vs SLGL, FULC vs VMD.